PURA - Puration Patented CBD Extraction Process Highlighted In Generex Shareholder Call
December 03 2018 - 2:01PM
InvestorsHub NewsWire
PURA - Puration Patented CBD
Extraction Process Highlighted In Generex Shareholder Call
Dallas, TX -- December 3, 2018 -- InvestorsHub
NewsWire -- Puration, Inc. (USOTC:
PURA) today announced that the company’s CBD Beverage Deal with Generex was a
highlighted topic in today’s Generex Biotechnology Corp. (OTCQB:
GNBT) shareholder conference call. The deal was discussed
in both the Generex Management Presentation and discussed again in
response to shareholder questions when CEO Joseph Moscato addressed
the quality and caliber of the underlying extraction process
utilized by Puration. Puration has the sole license for
beverage production of U.S. Patent
No. 9,199,960 entitled 'METHOD AND APPARATUS FOR PROCESSING
HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT'. The
patented is owned by Puration partner Kali, Inc. (USOTC:
KALY) and Kali will assist Puration in the deal with Generex in
the formulation of specific extract concentrates to address Generex
defined therapies.
For more
information on Puration, visit www.purationinc.com
For more
information on Generex, please visit: www.Generex.com
Disclaimer/Safe
Harbor:
This news
release contains forward-looking statements within the meaning of
the Securities Litigation Reform Act. The statements reflect the
Company's current views with respect to future events that involve
risks and uncertainties. Among others, these risks include the
expectation that any of the companies mentioned herein will achieve
significant sales, the failure to meet schedule or performance
requirements of the companies' contracts, the companies' liquidity
position, the companies' ability to obtain new contracts, the
emergence of competitors with greater financial resources and the
impact of competitive pricing. In the light of these uncertainties,
the forward-looking events referred to in this release might not
occur. These statements have not been evaluated by the Food and
Drug Administration. These products are not intended to diagnose,
treat, cure, or prevent any disease.
Puration, Inc.
Brian Shibley,
info@aciconglomerated.com
(800) 861-1350
Kali (CE) (USOTC:KALY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Kali (CE) (USOTC:KALY)
Historical Stock Chart
From Apr 2023 to Apr 2024